(ABT) Abbott Laboratories - Ratings and Ratios
Pharmaceuticals, Diagnostics, Nutrition, Devices, Generic
ABT EPS (Earnings per Share)
ABT Revenue
Description: ABT Abbott Laboratories
Abbott Laboratories (NYSE: ABT) operates globally across four core segments-Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices-leveraging a diversified portfolio that spans generic drugs, vaccines, point-of-care diagnostics, infant nutrition, cardiovascular implants, diabetes monitoring, and neuromodulation therapies.
The pharmaceutical arm supplies generics for a wide array of conditions (e.g., pancreatic exocrine insufficiency, dyslipidemia, hypertension, migraine) and specialty anti-infectives such as clarithromycin, while the diagnostics division offers immunoassay, clinical chemistry, hematology, molecular PCR platforms, rapid lateral-flow tests for pathogens (including SARS-CoV-2 and influenza), and cardiometabolic testing kits. The nutrition segment includes pediatric formulas and adult health supplements, and the medical-device business covers rhythm-management, heart-failure, vascular, structural-heart, diabetes-care, and chronic-pain neuromodulation devices.
Recent financial metrics (FY 2023) show revenue of $43.1 billion, a diluted EPS of $2.86, and free cash flow of roughly $6.5 billion, supporting a dividend yield near 1.5 % and a 2024-2025 share-repurchase plan of $5 billion. Abbott’s R&D spend averaged $3.2 billion (≈7.4 % of sales), reflecting its commitment to pipeline renewal in high-growth areas such as molecular diagnostics and cardiovascular devices. These figures are subject to macro-economic volatility, particularly currency fluctuations and US healthcare policy shifts, which could materially affect earnings.
Key sector drivers include an aging U.S. and global population that fuels demand for chronic-disease therapeutics, sustained growth in point-of-care testing accelerated by post-pandemic health-security concerns, and incremental pricing pressure from generic competition. Assuming continued reimbursement stability and no major supply-chain disruptions, Abbott’s diversified exposure positions it to capture a portion of the projected 5-6 % CAGR in global medical-device spend over the next five years.
For a deeper, data-driven valuation framework, the ValueRay platform provides granular scenario analysis that can help quantify Abbott’s upside and downside risks.
ABT Stock Overview
| Market Cap in USD | 232,021m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1978-01-13 |
ABT Stock Ratings
| Growth Rating | 58.7% |
| Fundamental | 71.7% |
| Dividend Rating | 64.5% |
| Return 12m vs S&P 500 | 1.88% |
| Analyst Rating | 4.11 of 5 |
ABT Dividends
| Dividend Yield 12m | 1.75% |
| Yield on Cost 5y | 2.28% |
| Annual Growth 5y | 11.18% |
| Payout Consistency | 96.8% |
| Payout Ratio | 54.6% |
ABT Growth Ratios
| Growth Correlation 3m | 81.8% |
| Growth Correlation 12m | 72.5% |
| Growth Correlation 5y | 31.6% |
| CAGR 5y | 11.62% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.56 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.79 |
| Sharpe Ratio 12m | 0.73 |
| Alpha | 5.94 |
| Beta | 0.696 |
| Volatility | 18.42% |
| Current Volume | 5653.5k |
| Average Volume 20d | 5362.2k |
| Stop Loss | 128.5 (-3.1%) |
| Signal | 0.11 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (13.98b TTM) > 0 and > 6% of Revenue (6% = 2.59b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 0.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 25.58% (prev 22.98%; Δ 2.60pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 9.04b <= Net Income 13.98b (YES >=105%, WARN >=100%) |
| Net Debt (6.49b) to EBITDA (11.61b) ratio: 0.56 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.75b) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 52.79% (prev 50.63%; Δ 2.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 54.91% (prev 55.77%; Δ -0.86pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 14.78 (EBITDA TTM 11.61b / Interest Expense TTM 573.0m) >= 6 (WARN >= 3) |
Altman Z'' 5.59
| (A) 0.13 = (Total Current Assets 24.47b - Total Current Liabilities 13.44b) / Total Assets 84.00b |
| (B) 0.58 = Retained Earnings (Balance) 48.47b / Total Assets 84.00b |
| (C) 0.11 = EBIT TTM 8.47b / Avg Total Assets 78.51b |
| (D) 2.03 = Book Value of Equity 67.17b / Total Liabilities 33.17b |
| Total Rating: 5.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 71.66
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 2.84% = 1.42 |
| 3. FCF Margin 15.72% = 3.93 |
| 4. Debt/Equity 0.27 = 2.47 |
| 5. Debt/Ebitda 0.56 = 2.26 |
| 6. ROIC - WACC (= 3.40)% = 4.26 |
| 7. RoE 29.93% = 2.49 |
| 8. Rev. Trend 69.36% = 5.20 |
| 9. EPS Trend -17.34% = -0.87 |
What is the price of ABT shares?
Over the past week, the price has changed by -0.87%, over one month by -0.87%, over three months by +0.86% and over the past year by +15.24%.
Is Abbott Laboratories a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ABT is around 127.72 USD . This means that ABT is currently overvalued and has a potential downside of -3.66%.
Is ABT a buy, sell or hold?
- Strong Buy: 12
- Buy: 7
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ABT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 143 | 7.9% |
| Analysts Target Price | 143 | 7.9% |
| ValueRay Target Price | 142 | 7.1% |
Last update: 2025-10-11 05:00
ABT Fundamental Data Overview
P/E Trailing = 16.7265
P/E Forward = 23.3645
P/S = 5.3822
P/B = 4.5775
P/EG = 4.1675
Beta = 0.696
Revenue TTM = 43.11b USD
EBIT TTM = 8.47b USD
EBITDA TTM = 11.61b USD
Long Term Debt = 12.93b USD (from longTermDebt, last quarter)
Short Term Debt = 507.0m USD (from shortTermDebt, last quarter)
Debt = 13.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.49b USD (from netDebt column, last quarter)
Enterprise Value = 238.51b USD (232.02b + Debt 13.44b - CCE 6.95b)
Interest Coverage Ratio = 14.78 (Ebit TTM 8.47b / Interest Expense TTM 573.0m)
FCF Yield = 2.84% (FCF TTM 6.78b / Enterprise Value 238.51b)
FCF Margin = 15.72% (FCF TTM 6.78b / Revenue TTM 43.11b)
Net Margin = 32.43% (Net Income TTM 13.98b / Revenue TTM 43.11b)
Gross Margin = 52.79% ((Revenue TTM 43.11b - Cost of Revenue TTM 20.35b) / Revenue TTM)
Gross Margin QoQ = 56.44% (prev 52.56%)
Tobins Q-Ratio = 2.84 (Enterprise Value 238.51b / Total Assets 84.00b)
Interest Expense / Debt = 0.90% (Interest Expense 121.0m / Debt 13.44b)
Taxrate = 17.26% (371.0m / 2.15b)
NOPAT = 7.01b (EBIT 8.47b * (1 - 17.26%))
Current Ratio = 1.82 (Total Current Assets 24.47b / Total Current Liabilities 13.44b)
Debt / Equity = 0.27 (Debt 13.44b / totalStockholderEquity, last quarter 50.56b)
Debt / EBITDA = 0.56 (Net Debt 6.49b / EBITDA 11.61b)
Debt / FCF = 0.96 (Net Debt 6.49b / FCF TTM 6.78b)
Total Stockholder Equity = 46.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.64% (Net Income 13.98b / Total Assets 84.00b)
RoE = 29.93% (Net Income TTM 13.98b / Total Stockholder Equity 46.71b)
RoCE = 14.20% (EBIT 8.47b / Capital Employed (Equity 46.71b + L.T.Debt 12.93b))
RoIC = 11.56% (NOPAT 7.01b / Invested Capital 60.65b)
WACC = 8.15% (E(232.02b)/V(245.46b) * Re(8.58%) + D(13.44b)/V(245.46b) * Rd(0.90%) * (1-Tc(0.17)))
Discount Rate = 8.58% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.09%
[DCF Debug] Terminal Value 75.15% ; FCFE base≈6.33b ; Y1≈5.88b ; Y5≈5.38b
Fair Price DCF = 50.28 (DCF Value 87.51b / Shares Outstanding 1.74b; 5y FCF grow -9.03% → 3.0% )
EPS Correlation: -17.34 | EPS CAGR: -4.61% | SUE: 0.91 | # QB: 1
Revenue Correlation: 69.36 | Revenue CAGR: 2.50% | SUE: 0.83 | # QB: 0
Additional Sources for ABT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle